UnknownPhase 4

Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy

Italy240 participantsStarted 2011-11

Plain-language summary

Patients who developed an acute coronary syndrome despite dual antiplatelet therapy with aspirin and clopidogrel may benefit from a further dose of clopidogrel before a percutaneous coronary intervention. The aim of this study is to evaluate safety and effectiveness of clopidogrel reloading in patients on chronic clopidogrel therapy with acute coronary syndrome undergoing percutaneous coronary intervention.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * chronic (\> 10 days) therapy with clopidogrel (75 mg/day) * non-ST-segment elevation acute coronary syndrome (ACS) requiring early diagnostic angiography Exclusion Criteria: * primary percutaneous coronary intervention (PCI) for acute ST-segment elevation acute myocardial infarction * platelet count \< 70 × 10\^9/L * high bleeding risk * coronary bypass grafting in the previous 3 months

What they're measuring

Major Adverse Cardiovascular Events

Timeframe: 30 days

Trial details

NCT IDNCT01572129

SponsorCampus Bio-Medico University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-05

Contact for this trial

Giuseppe Patti, MD

06225411899 g.patti@unicampus.it

View on ClinicalTrials.gov More Acute Coronary Syndrome trials